Cargando…
Dual Monoclonal Antibody Therapy for a Severe Asthma Patient
INTRODUCTION: Omalizumab, the first biological treatment for severe allergic bronchial asthma, has been on the market for more than a decade. Omalizumab was initially considered to be an IgE-blocking agent, and therefore, an inhibitor of the Th2 (allergic or adaptive) cascade. More recently, other m...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7556278/ https://www.ncbi.nlm.nih.gov/pubmed/33101041 http://dx.doi.org/10.3389/fphar.2020.587621 |